%0 Generic
%A Lacerenza, S.
%A Moura, D.
%A Pena-Chilet, M.
%A Hindi, N.
%A Dopazo, J.
%A Sanchez-Bustos, P.
%A Grignani, G.
%A Martinez-Trufero, J.
%A Redondo, A.
%A Valverde, C.
%A Stacchiotti, S.
%A Lopez-Pousa, A.
%A D'Ambrosio, L.
%A Perez-Vega, H.
%A Collini, P.
%A Lopez-Martin, J. A.
%A Martin-Broto, J.
%T Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups
%D 2021
%@ 0923-7534
%U https://hdl.handle.net/10668/27455
%X Immunomodulation has emerged as an active therapeutic option in some solid tumors; however, the efficacy of immunotherapy-based regimens is limited in sarcomas or restricted to a few specific subtypes. IMMUNOSARC was a phase Ib/II trial testing the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab) in bone and soft-tissue sarcoma (STS). In this latter cohort, the trial met its primary endpoint, with 48% of patients free of progression at 6 months (m). We present here, part of the correlative studies associated with the STS cohort.
%K Humans
%K Programmed Cell Death 1 Receptor
%K Immunotherapy
%K Angiogenesis
%~